This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

AboutAboutEfficacyMOAMist MomentsSafety & DosingSafety &
Dosing
SafetyDosing
PrescribingPrescribingAccess & SavingsZavzpret OneSourcePractice ResourcesPractice ResourcesEventsMaterialsVideosPA Resources
Prescribing InformationPatient Information Instructions for UseIndication Press Release
One stop for resources and personalized patient supportOne stop for resources and personalized patient support

Help your patients access ZAVZPRET with our dedicated savings and support program.




Call 1-877-ZAVZPRET and a Zavzpret OneSource representative will assist you.

Access for your eligible, commercially insured patients

  • Eligible patients may access ZAVZPRET at no cost while benefits are being verified*
  • Pay as little as $0 with the ZAVZPRET copay card

*As long as coverage is being investigated until the end of 2023. For 1 Rx fill only.

*As long as coverage is being investigated until the end of 2023. For 1 RX fill only.

Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For full terms and conditions or any questions, please call 1-800-761-1568, visit zavzpret.com/copay-termsor write to Pfizer Inc. at PO Box 29387, Mission, KS 66201.

Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico.The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For full terms and conditions or any questions, please call 1-800-761-1568, visit zavzpret.com/copay-terms or write to Pfizer Inc. at PO Box 29387, Mission, KS 66201.

No enrollment forms, just prescribe

Getting started:
  1. ePrescribe: Select ASPN Pharmacies, LLC in your EMR
  2. Patient Outreach: ASPN Pharmacies contacts patients within 2 hours
    • Give your patient a OneSource Intro Card so they know what to expect 
  3. Prescription Delivery: Shipped to patient's home or they can opt to pickup from their local pharmacy
Explore HCP and patient resources

Including OneSource overview, info sheets, and more.

See more Loading
Prescribing Connect with a sales representative to learn more Request a representative Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-ZAZ-USA-0093
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367


​​​​​​​
INDICATION

ZAVZPRETTM (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Important Safety Information Contraindications: Hypersensitivity to ZAVZPRET or any of its components.

Warnings and Precautions: Hypersensitivity reactions, including facial swelling and urticaria, have occurred with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.

Adverse Reactions: Most common adverse reactions (occurring in ≥2% of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs 1%).

Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.

Use in Specific Populations: Hepatic Impairment: Avoid use in patients with severe hepatic impairment. Renal impairment: Avoid use of ZAVZPRET in patients with creatinine clearance (CLcr) less than 30 mL/min.

Please click here for full Prescribing Information.
IndicationZAVZPRET™️ (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Please see Full Prescribing Information.